Abby B. Siegel

Data from Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study

Richard S. Finn, Masatoshi Kudo, Ivan Borbath, Julien Edeline et autres

AbstractPurpose: In the phase II KEYNOTE-224 study, pembrolizumab showed durable antitumor activity and manageable safety in participants with sorafenib-treated (cohort 1) or treatment-naïve (cohort 2) advanced hepatocellular carcinoma (HCC). We present data after a median follow-up of ∼7 years for cohort 1 …

Supplementary Table S1 from Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study

Richard S. Finn, Masatoshi Kudo, Ivan Borbath, Julien Edeline et autres

Table S1. Representativeness of study participants.

Supplementary Figure S1 from Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study

Richard S. Finn, Masatoshi Kudo, Ivan Borbath, Julien Edeline et autres

Supplementary Figure S1. Kaplan-Meier estimates of (A) DOR, (B) PFS, and (C) TTP per RECIST v1.1 by BICR

Economic Burden of Recurrence in Early-Stage Hepatocellular Carcinoma Treated with Surgical Resection or Local Ablation in the United States: A Retrospective Analysis of Surveillance, Epidemiology and End Results–Medicare Data

Neil Mehta, Liya Wang, Shital Kamble, Y. Song et autres

Patients with early-stage hepatocellular carcinoma (HCC) who undergo curative-intent therapy remain at risk of disease recurrence. This study aimed to quantify the economic burden associated with disease recurrence in these patients. Patients ≥ 66 years old with early-stage HCC who have achieved …

us (code pays fourni par la source)

Recurrence-free survival as a predictor of overall survival among patients with early-stage hepatocellular carcinoma treated with surgical resection or local ablation

Neil Mehta, Kaushal D. Desai, Shital Kamble, Yan Song et autres

Background This study describes clinical outcomes of patients with hepatocellular carcinoma (HCC) and evaluates the association between real-world recurrence-free survival (rwRFS) and real-world overall survival (rwOS). Methods Patients with HCC who had no evidence of disease or treatment within 30 days of …

us (code pays fourni par la source)

Data from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

AbstractPurpose: In the randomized phase 3 KEYNOTE-966 trial, first-line pembrolizumab plus chemotherapy significantly improved overall survival (OS) versus placebo plus chemotherapy for participants with advanced biliary tract cancer (BTC). This post hoc analysis investigated whether hepatitis B virus (HBV) infection affected the …

Table S4 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

Representativeness of study participants.

Table 1 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

Baseline demographics and disease characteristics by HBV infection status (ITT population).

Figure S2 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

Figure S2 shows time course of HBV DNAa and ALT levels, duration of treatment, and initiation of new antiviral therapy in participants with chronic HBV at baseline who experienced HBV reactivation during the study

Table S1 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

Baseline demographic and disease characteristics by chronic and clinically resolved HBV infection (ITT population)

Table 2 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

HBV-related outcomes in evaluable participants with HBV infectiona.

Figure S1 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

Figure S1 shows time course of HBV DNAa and ALT levels, duration of treatment, and initiation of new antiviral therapy in participants with clinically resolved HBV at baseline who experienced HBV reactivation during the study